Participants 100 427 5
(Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) is the first major study to compare an angiotensin II Type 1 antagonist losartan (Cozaar trade mark, Merck) with an ACE inhibitor captonpril (Capoten trade mark, Elan) after myocardial infarction in patients with left ventricular dysfunction.
Participants 428 531 4
Patients were assigned to a target dose of losartan 50 mg/day and captopril 50 mg t.i.d., as tolerated.
